Cartesian Therapeutics (RNAC) Other Working Capital Changes (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Other Working Capital Changes for 8 consecutive years, with -$412000.0 the latest figure, recorded in Q2 2024.

• In Q2 2024, Other Working Capital Changes rose 37.0% year-over-year to -$412000.0; the TTM figure through Mar 2025 stood at -$412000.0 (up 95.59% YoY), while the FY2024 annual figure was -$5.8 million, down 211.28% from the prior year.
• Other Working Capital Changes grew to -$412000.0 in Q2 2024 per RNAC's latest filing, from -$5.4 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $5.8 million in Q1 2025 and bottomed at -$2.8 million in Q4 2022.
• Historically, Other Working Capital Changes has averaged $152411.8 across 5 years, with a median of -$70000.0 in 2022.
• On a YoY basis, Other Working Capital Changes climbed as much as 4875700.0% in 2020 and fell as far as 1542.86% in 2020.
• Cartesian Therapeutics' Other Working Capital Changes stood at -$5.0 million in 2020, then tumbled by 238.06% to -$17.1 million in 2021, then surged by 49.26% to -$8.7 million in 2022, then surged by 73.77% to -$2.3 million in 2023, then soared by 81.87% to -$412000.0 in 2024.
• Business Quant data shows RNAC's Other Working Capital Changes at -$412000.0 in Q2 2024, -$5.4 million in Q1 2024, and -$2.3 million in Q4 2023.